Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.9076
-0.0103 (-1.12%)
At close: Apr 1, 2025, 4:00 PM
0.9000
-0.0076 (-0.84%)
After-hours: Apr 1, 2025, 5:42 PM EDT
Clearside Biomedical Employees
Clearside Biomedical had 30 employees as of December 31, 2023. The number of employees decreased by 6 or -16.67% compared to the previous year.
Employees
30
Change (1Y)
-6
Growth (1Y)
-16.67%
Revenue / Employee
$55,467
Profits / Employee
-$1,145,067
Market Cap
70.02M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CLSD News
- 11 hours ago - Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 days ago - Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript - Seeking Alpha
- 5 days ago - Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 days ago - Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - GlobeNewsWire
- 12 days ago - Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit - GlobeNewsWire
- 20 days ago - Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 - GlobeNewsWire
- 26 days ago - Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD - GlobeNewsWire
- 5 weeks ago - Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema - GlobeNewsWire